1.Therapeutic Potential of Methanol Extract of Euonymus alatus in HT22 Cells Through Neuroprotective Mechanisms
Natural Product Sciences 2025;31(1):49-54
Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.
2.Therapeutic Potential of Methanol Extract of Euonymus alatus in HT22 Cells Through Neuroprotective Mechanisms
Natural Product Sciences 2025;31(1):49-54
Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.
3.Therapeutic Potential of Methanol Extract of Euonymus alatus in HT22 Cells Through Neuroprotective Mechanisms
Natural Product Sciences 2025;31(1):49-54
Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.
4.Eligibility for Lecanemab Treatment in the Republic of Korea:Real-World Data From Memory Clinics
Sung Hoon KANG ; Jee Hyang JEONG ; Jung-Min PYUN ; Geon Ha KIM ; Young Ho PARK ; YongSoo SHIM ; Seong-Ho KOH ; Chi-Hun KIM ; Young Chul YOUN ; Dong Won YANG ; Hyuk-je LEE ; Han LEE ; Dain KIM ; Kyunghwa SUN ; So Young MOON ; Kee Hyung PARK ; Seong Hye CHOI
Journal of Clinical Neurology 2025;21(3):182-189
Background:
and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.
Methods:
We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.
Results:
When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.
Conclusions
Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.
5.Eligibility for Lecanemab Treatment in the Republic of Korea:Real-World Data From Memory Clinics
Sung Hoon KANG ; Jee Hyang JEONG ; Jung-Min PYUN ; Geon Ha KIM ; Young Ho PARK ; YongSoo SHIM ; Seong-Ho KOH ; Chi-Hun KIM ; Young Chul YOUN ; Dong Won YANG ; Hyuk-je LEE ; Han LEE ; Dain KIM ; Kyunghwa SUN ; So Young MOON ; Kee Hyung PARK ; Seong Hye CHOI
Journal of Clinical Neurology 2025;21(3):182-189
Background:
and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.
Methods:
We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.
Results:
When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.
Conclusions
Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.
6.Therapeutic Potential of Methanol Extract of Euonymus alatus in HT22 Cells Through Neuroprotective Mechanisms
Natural Product Sciences 2025;31(1):49-54
Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.
7.Eligibility for Lecanemab Treatment in the Republic of Korea:Real-World Data From Memory Clinics
Sung Hoon KANG ; Jee Hyang JEONG ; Jung-Min PYUN ; Geon Ha KIM ; Young Ho PARK ; YongSoo SHIM ; Seong-Ho KOH ; Chi-Hun KIM ; Young Chul YOUN ; Dong Won YANG ; Hyuk-je LEE ; Han LEE ; Dain KIM ; Kyunghwa SUN ; So Young MOON ; Kee Hyung PARK ; Seong Hye CHOI
Journal of Clinical Neurology 2025;21(3):182-189
Background:
and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment.
Methods:
We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study.
Results:
When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22.
Conclusions
Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.
8.Therapeutic Potential of Methanol Extract of Euonymus alatus in HT22 Cells Through Neuroprotective Mechanisms
Natural Product Sciences 2025;31(1):49-54
Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.
9.Immune Cells Are DifferentiallyAffected by SARS-CoV-2 Viral Loads in K18-hACE2 Mice
Jung Ah KIM ; Sung-Hee KIM ; Jeong Jin KIM ; Hyuna NOH ; Su-bin LEE ; Haengdueng JEONG ; Jiseon KIM ; Donghun JEON ; Jung Seon SEO ; Dain ON ; Suhyeon YOON ; Sang Gyu LEE ; Youn Woo LEE ; Hui Jeong JANG ; In Ho PARK ; Jooyeon OH ; Sang-Hyuk SEOK ; Yu Jin LEE ; Seung-Min HONG ; Se-Hee AN ; Joon-Yong BAE ; Jung-ah CHOI ; Seo Yeon KIM ; Young Been KIM ; Ji-Yeon HWANG ; Hyo-Jung LEE ; Hong Bin KIM ; Dae Gwin JEONG ; Daesub SONG ; Manki SONG ; Man-Seong PARK ; Kang-Seuk CHOI ; Jun Won PARK ; Jun-Won YUN ; Jeon-Soo SHIN ; Ho-Young LEE ; Ho-Keun KWON ; Jun-Young SEO ; Ki Taek NAM ; Heon Yung GEE ; Je Kyung SEONG
Immune Network 2024;24(2):e7-
Viral load and the duration of viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are important determinants of the transmission of coronavirus disease 2019.In this study, we examined the effects of viral doses on the lung and spleen of K18-hACE2 transgenic mice by temporal histological and transcriptional analyses. Approximately, 1×105 plaque-forming units (PFU) of SARS-CoV-2 induced strong host responses in the lungs from 2 days post inoculation (dpi) which did not recover until the mice died, whereas responses to the virus were obvious at 5 days, recovering to the basal state by 14 dpi at 1×102 PFU. Further, flow cytometry showed that number of CD8+ T cells continuously increased in 1×102 PFU-virusinfected lungs from 2 dpi, but not in 1×105 PFU-virus-infected lungs. In spleens, responses to the virus were prominent from 2 dpi, and number of B cells was significantly decreased at 1×105PFU; however, 1×102 PFU of virus induced very weak responses from 2 dpi which recovered by 10 dpi. Although the defense responses returned to normal and the mice survived, lung histology showed evidence of fibrosis, suggesting sequelae of SARS-CoV-2 infection. Our findings indicate that specific effectors of the immune response in the lung and spleen were either increased or depleted in response to doses of SARS-CoV-2. This study demonstrated that the response of local and systemic immune effectors to a viral infection varies with viral dose, which either exacerbates the severity of the infection or accelerates its elimination.
10.Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Overview and Summary 2024
Young Joo PARK ; Eun Kyung LEE ; Young Shin SONG ; Bon Seok KOO ; Hyungju KWON ; Keunyoung KIM ; Mijin KIM ; Bo Hyun KIM ; Won Gu KIM ; Won Bae KIM ; Won Woong KIM ; Jung-Han KIM ; Hee Kyung KIM ; Hee Young NA ; Shin Je MOON ; Jung-Eun MOON ; Sohyun PARK ; Jun-Ook PARK ; Ji-In BANG ; Kyorim BACK ; Youngduk SEO ; Dong Yeob SHIN ; Su-Jin SHIN ; Hwa Young AHN ; So Won OH ; Seung Hoon WOO ; Ho-Ryun WON ; Chang Hwan RYU ; Jee Hee YOON ; Ka Hee YI ; Min Kyoung LEE ; Sang-Woo LEE ; Seung Eun LEE ; Sihoon LEE ; Young Ah LEE ; Joon-Hyop LEE ; Ji Ye LEE ; Jieun LEE ; Cho Rok LEE ; Dong-Jun LIM ; Jae-Yol LIM ; Yun Kyung JEON ; Kyong Yeun JUNG ; Ari CHONG ; Yun Jae CHUNG ; Chan Kwon JUNG ; Kwanhoon JO ; Yoon Young CHO ; A Ram HONG ; Chae Moon HONG ; Ho-Cheol KANG ; Sun Wook KIM ; Woong Youn CHUNG ; Do Joon PARK ; Dong Gyu NA ;
International Journal of Thyroidology 2024;17(1):1-20
Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.

Result Analysis
Print
Save
E-mail